TIGER is the first challenge on fully automated assessment of tumor-infiltrating lymphocytes (TILs) in H&E breast cancer slides. It is organized by the Diagnostic Image Analysis Group (DIAG) of the Radboud University Medical Center (Radboudumc) in Nijmegen (The Netherlands), in close collaboration with the International Immuno-Oncology Biomarker working Group (www.tilsinbreastcancer.org).
The goal of this challenge is to evaluate new computer algorithms for the automated assessment of tumor-infiltrating lymphocytes (TILs) in Her2 positive and Triple Negative breast cancer (BC) histopathology slides. In recent years, several studies have shown the predictive and prognostic value of visually scored TILs in BC as well as in other cancer types, making TILs a powerful biomarker that can potentially be used in the clinic. With TIGER, we aim at developing computer algorithms that can automatically generate a “TIL score” with a high prognostic value.